Company: NCNA
Filing Date: 2025-04-24
Form Type: DRSLTR
Source: 0000950123-25-003671
Chunk: 2

Company: NuCana plc
Filing Date: 2025-04-24
Form: DRSLTR
Chunk 2
---
 maximum number of ADSs that may be issuable upon exercise of all of the Warrants. Response 3: The Company respectfully acknowledges the Staff’s comment and has revised the risk factor on page 11 of the Form F-1in accordance with the Staff’s comment. Comment 4: Please include a risk factor stating, if true, that this offering could cause the price of your ADSs to fall below the minimum bid price required by the Nasdaq Listing Rules, which could result in your ADSs being delisted from Nasdaq. To the extent you have plans to seek shareholder approval for a reverse stock split or have plans to increase the number of ordinary shares represented by your ADSs, please disclose such plans in this registration statement, including the proposed ratio, if known. Response 4: The Company respectfully acknowledges the Staff’s comment and has added a risk factor on page 11 of the Form F-1in accordance with the Staff’s comment. General Comment 5: We note your references in your prospectus to an “alternative cashless exercise” of the Series B Warrants. The term “cashless exercise” is generally understood to allow a warrant holder to exercise a warrant without paying cash for the exercise price and reducing the number of shares receivable by the holder by an amount equal in value to the aggregate exercise price the holder would otherwise pay to exercise the warrants.

In cashless exercises, it is expected that the warrant holder receives fewer shares than they would if they opted to pay the exercise price in cash. Please clarify your disclosure throughout the prospectus by removing the references to “alternative cashless exercise” and exclusively using the term “zero exercise price” or another appropriate term that conveys that, in addition to the company receiving no, or nominal, cash upon the “alternative cashless exercise,” the warrant holders would be entitled to receive more ADSs than they would under the cash exercise terms. Response 5: The Company respectfully acknowledges the Staff’s comment and has revised these references using the term “zero exercise price” in the Form F-1in accordance with the Staff’s comment. * * * * * We hope that the above response will be acceptable to the Staff. Please do not hesitate to call me at (617) 348-3050with any comments or questions regarding the proposed disclosure. We thank you for your time and attention.

| Sincerely,       |
| /s/ John T. Rudy |
| John T. Rudy     |

| cc: |     |                                                                |
|     |